Anti Cancer
Anti Cancer - Related Videos
09:26
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
0 Views •
Cited by 8 •
2011
Here, we established a method for drug efficacy testing with surgical specimens of brain tumors, termed “tumor explant method”. With this method, we can evaluate drug efficacy without breaking the microenvironment of solid tumors. To validate reliability of this method, we describe representative data with our glioma specimen treated with the current first-line chemotherapeutic agent, temozolomide.
10:16
Chick Heart Invasion Assay for Testing the Invasiveness of Cancer Cells and the Activity of Potentially Anti-invasive Compounds
0 Views •
Cited by 4 •
2015
Here, we present a protocol to study the invasion of tumor cells into living normal tissue fragments in three dimensions. This organ culture technique is mainly applied to test potentially anti-invasive drugs in vitro.
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
0 Views •
Cited by 13 •
2016
Here, we describe a method of long-term time-lapse microscopy to longitudinally track single cells in response to anti-cancer therapeutics.
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
0 Views •
Cited by 13 •
2017
Resistance to cancer therapies contributes to disease progression and death. Determining the mechanistic underpinnings of resistance is crucial for improving therapeutic response. This manuscript details the protocol to generate taxane-resistant cell models of prostate cancer (PC) to help dissecting the pathways involved in progression to Docetaxel resistance in PC patients.
10:15
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
0 Views •
Cited by 46 •
2015
Neutrophils play an important role not only in host defense against invading microorganisms, but are also involved in the immune surveillance of tumor cells. Here, we describe techniques related to the isolation of neutrophils with anti-tumor properties and methods for monitoring anti-tumor neutrophil function in vitro and in vivo.
FAQs
DNA damage can interfere with the ability of malignant cells to continue surviving and multiplying. This mechanism is especially relevant when treatment aims to slow tumor growth or eliminate cancerous tissue. Its medical value depends on selecting an approach appropriate to the tumor and patient, because limiting harm to healthy tissue remains an important treatment goal.
Blocking growth and survival signals targets the internal messages that help malignant cells persist and expand. Inhibiting blood-vessel formation acts on the tumor’s ability to obtain the vascular support needed for continued growth. These mechanisms address different biological requirements, so distinguishing them helps explain why anticancer strategies can act on separate parts of tumor development.
Immune-based approaches seek to activate the immune system so it can recognize and destroy malignant cells. This differs from directly damaging tumor DNA or blocking a growth signal, because the treatment engages an existing biological defense system. In medicine, that mechanism provides another route for attacking cancer while treatment plans still consider tumor type, stage, and patient factors.
Molecular features can help distinguish which biological processes are important in a particular tumor. Because anticancer therapies may target DNA, growth and survival signals, blood-vessel formation, or immune recognition, these features contribute to choosing a suitable strategy. Their consideration supports more individualized care alongside tumor type, stage, and factors related to the patient.
Selection is guided by the tumor type, disease stage, molecular features, and patient factors. These considerations help clinicians match the intended mechanism and intensity of treatment to the clinical situation. The decision also balances disease control against possible harm to healthy tissue, with care directed toward controlling cancer, reducing recurrence, extending survival, and preserving quality of life.
These approaches represent different treatment options within anticancer care. Surgery and radiation are included among the available interventions, while chemotherapy, targeted therapy, and immunotherapy represent additional therapeutic strategies. Their use is not determined by a single universal plan; clinicians select among them according to the cancer’s characteristics, stage, molecular features, and the patient’s circumstances.
Success can be considered through several clinical goals rather than one measure alone. Care may aim to control the disease, reduce the chance of recurrence, extend survival, or improve quality of life. Evaluating these outcomes keeps treatment focused on both cancer-related benefit and the need to limit unnecessary harm to healthy tissue.